

# Stock Update

To become a strong and healthier consumer play


## Hindustan Unilever

Reco: Buy | CMP: Rs1,826


### Company details

Price target:	Rs2,071
Market cap:	Rs395,265 cr
52-week high/low:	Rs1840/1241
NSE volume: (No of shares)	14.4 lakh
BSE code:	500696
NSE code:	HINDUNILVR
Sharekhan code:	HINDUNILVR
Free float: (No of shares)	71.0 cr

### Shareholding pattern



### Price chart



### Price performance

(%)	1m	3m	6m	12m
Absolute	8.2	-0.9	10.3	39.7
Relative to Sensex	2.8	5.5	6.8	26.4

### Key points

- Event – GSK Consumers acquisition will boost HUL growth prospects and will be earnings accretive: The board of Hindustan Unilever Limited (HUL) has approved the merger of 100% Glaxo SmithKline Consumer (GSK Consumer) with itself for a transaction cost of Rs. 31,700 crore (price to sales of 6.5x) and subject to regulatory and shareholder approvals. The transaction is an all-equity merger with 4.39 shares of HUL being allotted for every one share held in GSK Consumer (equity dilution of 8.5%). GSK Consumer's business includes strong brands such as Horlicks, Boost and Maltova in the health food drinks (HFD) category coupled with over-the-counter and oral health products in India. With a strong brand portfolio, GSK Consumer has a leadership position in the domestic HFD category with about 60% market share (Horlicks has a volume market share of 49%). Though the swap ratio is favourable for GSK Consumers, the deal is EPS accretive for HUL as it brings in incremental PAT of Rs. 700 crore (13% up as per FY2018 financials), while equity capital gets diluted by just 8.5% due to the deal. Moreover, the company would further gain from synergy benefits and consolidate its leadership position in the high-growth and high-margin health food business. Post the merger, Unilever Plc's (parent company of HUL) holding in HUL will be diluted from 67.2% to 61.9%, while GSK Plc (including group companies) will own 5.7% of the merged entity.

- Unlocking various synergistic benefits in the long run: Though in the past 2-3 years, the HFD category's growth has been muted due to several macro factors, India is attractive for the HFD category with lower penetration of 24% (as 80-85% of category revenue comes from the Eastern and Southern parts of India). Further, the category is a more urban-centric category with rural penetration standing at just 14%. With pan-India distribution reach of ~8 million outlets and a strong presence in the rural market, HUL is well poised to scale up the category's growth in the coming years. GSK Consumer has a strong brand portfolio to offer across many consumer segments [energy and everyday nourishment (Boost and Horlicks) life stages (Women Horlicks) and specific health needs (Horlicks - Growth plus, Protein plus)]. We

might see HUL launching new products under the existing brands/introducing new packs with adequate advertisement spends, which will help in acquiring new customers in the near future. HUL will also drive significant cost synergies from a combination of supply chain efficiencies and operational improvements, go-to-market and distribution network optimisation, scale in a number of cost areas such as marketing and streamlining of overlapping infrastructure. HUL expects the business to grow in double digits in the medium term and margins are expected to be accretive to HUL post realisation of synergy benefits.

- Deal is expected to be earnings accretive for HUL, maintain Buy with a revised PT of Rs. 2,071:** The acquisition is in-line with HUL's strategy to

acquire sustainable profitable business with a strong brand portfolio in the domestic market. As per our earnings estimates of GSK Consumer for FY20/21, the deal is earnings accretive (4-5% accretion) for HUL (with consolidated OPM standing at 20-21% and earnings reporting a CAGR of ~18% over FY2018-FY2021). A well-established distribution reach and new launches under the existing brands would help HUL's food business to grow in double digits and improve profitability in the coming years. Thus, we maintain our Buy recommendation on the stock with an upgraded price target (PT) of Rs. 2,071 (considering earnings accretion and strong growth prospects through the acquired brands). We are not including GSK Consumers' estimates in our current estimates of HUL as the deal will be complete over the next 12 months.

#### Valuation (Standalone)

Particulars	FY2017	FY2018	FY2019E*	FY2020E*	FY2021E*	Rs cr
Net sales (Rs. crore)	34,487.0	35,218.0	39,598.0	45,321.1	51,218.4	
Net profit (Rs crore)	42,490.0	5,286.6	61,978.8	7,362.4	8,740.7	
OPM (%)	17.5	20.7	21.5	21.3	21.7	
EPS (Rs.)	19.7	24.5	28.7	34.1	40.5	
PER (x)	92.8	74.6	63.6	53.6	45.1	
EV/EBIDTA (x)	64.4	53.2	45.1	39.3	33.6	
RoCE (%)	91.8	104.2	102.0	89.4	77.5	
RoNW (%)	66.6	77.9	74.9	65.3	56.3	

\* Estimates are excluding the recently acquired GSK Consumers financials

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Know more about our products and services

## For Private Circulation only

**Disclaimer:** This document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This Document is subject to changes without prior notice. This document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other reports that are inconsistent with and reach different conclusions from the information presented in this report.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licencing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst has not dealt or traded directly or indirectly in securities of the company and that all of the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst further certifies that neither he nor his relatives has any direct or indirect financial interest nor have actual or beneficial ownership of 1% or more in the securities of the company nor have any material conflict of interest nor has served as officer, director or employee or engaged in market making activity of the company. Further, the analyst has also not been a part of the team which has managed or co-managed the public offerings of the company and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Compliance Officer: Mr. Joby John Meledan; Tel: 022-61150000; email id: [compliance@sharekhan.com](mailto:compliance@sharekhan.com);

For any queries or grievances kindly email [igc@sharekhan.com](mailto:igc@sharekhan.com) or contact: [myaccount@sharekhan.com](mailto:myaccount@sharekhan.com)

**Registered Office:** Sharekhan Limited, 10th Floor, Beta Building, Lodha iThink Techno Campus, Off. JVLR, Opp. Kanjurmarg Railway Station, Kanjurmarg (East), Mumbai – 400042, Maharashtra. Tel: 022 - 61150000. Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669; Research Analyst: INH000006183;

Disclaimer: Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on [www.sharekhan.com](http://www.sharekhan.com); Investment in securities market are subject to market risks, read all the related documents carefully before investing.